Repeat stereotactic radiosurgery in the management of brain @entity3 from XXXX .

@entity1 @entity5 @entity75 @entity16 @entity1149 @entity3 @entity85
@entity1149 ( @entity1149 ) is characterized by brain @entity3 that occur in about 30 to 50% of @entity1 . To control @entity5 growth potential with maintaining neurocognitive function is important in the recent radiotherapy against brain @entity3 . From this viewpoint, we investigated the utility of repeat stereotactic radiosurgery (SRS) with a linear accelerator in the management of brain @entity3 from @entity1149 . Between October 1998 and May 2010, 28 @entity1 harboring brain @entity3 received repeat SRS (20 @entity1 and 8 @entity1 , with the age ranged from 51 to 79). The total number of SRS sessions ranged from 2 to 5, and the total number of lesions in one @entity1 ranged from 1 to 8. @entity16 due to uncontrolled @entity75 was identified in 9 of 28 @entity1 after the repeat SRS, while the remaining 19 @entity1 showed no neurological decline. Out of the 28 @entity1 , 18 @entity1 died by July 1, 2010; 12 @entity1 died of active @entity85 and 6 @entity1 died from progressive @entity75 , considered @entity16 . The 2-year and 4-year overall survival rates were 51% and 23%, respectively, and the median survival time was 26 months. In conclusion, repeat SRS is a preferred option to manage brain @entity3 from @entity1149 , leading to a long survival with a decreased neurological decline. Repeat SRS is promising to preserve neurocognition, because the convergent dose distribution decreases the unfavorable influences from radiation on germinal niches, thereby preserving neural stem cells that are responsible for the nervous system repair.
